Huge news out! $BETS going BIG. $$$$$$$$
BETS Announces Purchase of 3300 units of S19 Miners
December 01 2023 - 09:00AM
PR Newswire (US)
CHANGSHA, China, Dec. 1, 2023 /PRNewswire/ -- Bit Brother Limited (the "Company," "we", or "Bit Brother") (NASDAQ: BETS) is pleased to announce it purchased 3300 units of Antminer S19 miners, injecting powerful momentum into its Bitcoin mining operations.
This substantial investment is expected to propelled Bit Brother's total hash rate to 400,000 TH/s assuming the 3300 units are fully functioning, further solidifying its emerging position in the cryptocurrency mining arena. The Company's technical team, through relentless efforts, optimized the performance of the mining machines, enhancing mining efficiency to generate more substantial returns for investors.
Mr. Jack Wu, CEO of Bit Brother stated, "We are incredibly proud of the achievement we have made. This marks a significant success in our strategic expansion in the Bitcoin mining sector. The acquisition of Antminer S19 miners is part of our ongoing efforts to ensure our mining operations remain highly competitive."
About Bit Brother Limited
Bit Brother Ltd is a multifaceted corporation with operations spanning business management in China and blockchain and cryptocurrency ventures in the United States. Within the U.S. jurisdiction, the company strategically manages and integrates cryptocurrency mining facilities. With a dedicated team of specialists, company has successfully expanded two mining ventures and is committed to further growth. For more information, please visit: www.bitbrother.com.
Contact: contactus[ @
View original content:https://www.prnewswire.com/news-releases/bets-announces-purchase-of-3300-units-of-s19-miners-302003033.html
SOURCE Bit Brother Limited
Copyright 2023 PR Newswire
...more to come!! Stay tuned! $BETS $$$$$$$$
$NUWE > New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients
Tue, November 28, 2023 at 2:00 PM GMT+1
Recommendation Rating: Buy
The data demonstrate that the hematocrit sensor within the Nuwellis Aquadex® system offers unique advantages for fluid overloaded small patients
MINNEAPOLIS, Nov. 28, 2023 (GLOBE NEWSWIRE) -- New real-world data demonstrate that pediatric patients with fluid overload respond well to Aquadex® ultrafiltration therapy with continuous hematocrit monitoring, announced Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload. The publication, “Using Aquapheresis with Continuous Hematocrit Monitoring to Guide Ultrafiltration,” was featured in Pediatric Nephrology. 1
The publication is a single-center case study review of pediatric patients with hypoalbuminemia and severe fluid overload. Patients were treated with Nuwellis’ Aquadex® ultrafiltration therapy with continuous hematocrit monitoring to guide isotonic fluid removal. The study concluded that the therapy successfully treated small patients without hemodynamic instability or other complications, demonstrating that Aquadex is an effective treatment option for fluid overload.
“We’re proud to share new evidence supporting the clinical need and applications for Aquadex among pediatric patients, and we’re grateful to Dr. Michelle Starr and her colleagues for their trust and confidence in our therapy,” said Nestor Jaramillo, Jr., President and Chief Executive Officer of Nuwellis. “Our proprietary hematocrit sensor which is incorporated into the Aquadex console was a result of physician feedback and observations from clinical studies that drove us to make our Aquadex therapy even smarter. Our team is committed to supporting diuretic-resistant patients broadly, and I’m encouraged to see data validating this strategy as Nuwellis works to expand access to ultrafiltration to even more patients and clinicians.”
“Managing fluid overload for pediatric patients can be challenging, but these new data and our growing library of evidence support our view that Aquadex can provide a safe and effective method for restoring fluid balance,” said John Jefferies, MD, Chief Medical Officer of Nuwellis. “The continuous hematocrit monitoring function within the Aquadex provides unique and proprietary therapeutic direction, as demonstrated in this important publication.”
Effectively managing fluid overload for pediatric patients is critical. Fluid overload is associated with significant increases in mortality in pediatric patients. Research has shown that a 3% increase in mortality is observed for every 1% increase in fluid overload among these patients. 2,3
Aquadex is proven to simply, safely, and precisely remove excess fluid from patients suffering from fluid overload who have not responded to conventional medical management, including diuretics. Providers can specify and adjust the rate of fluid removed for each individual patient, resulting in a gradual reduction of excess fluid. The device’s built-in, customizable hematocrit monitoring technology provides real-time measurement of percent blood volume changes that can be tailored to individual patients’ needs. A customizable fluid removal rate is particularly important for pediatric patients, who have a small amount of blood in their bodies. The Aquadex system is cleared by the FDA for use in adults and pediatric patients weighing 20 kg (44 lbs.) or more.
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or Twitter.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
$BETS' Bitcoin Balance: 122.54707244 = $4.615.951!
Link to $BETS's $BTCUSD wallet > https://www.blockchain.com/de/explorer/addresses/btc/37frzvqQeAzf6hWj4J9zrEzZf4WJoo3sRR
$BETS >>> $53.33M Ca$h + BTC wallet at almost $5M!!! $$$$$$$
$BETS' Bitcoin-Wallet > https://www.blockchain.com/de/explorer/addresses/btc/37frzvqQeAzf6hWj4J9zrEzZf4WJoo3sRR
$BETS' Ca$h > https://dilutiontracker.com/app/search/BETS
$BETS >>> NEWS & SC_13G/A filing out!
News > https://finance.yahoo.com/news/bets-mined-over-120-btc-140000291.html
Filing > https://www.sec.gov/Archives/edgar/data/1543268/000198084023000011/mrBETS1129.htm
Right-on, that big investor got even bigger meanwhile.
Uppered his stake from 11,705,996 up to 14,680,996 shares of $BETS.
SC_13G/A filing can be viewed by everyone in the appendix below.
S-8 filing with employee incentive plan:
$CYTO >>> 17.01M O/S vs. 224.2M (illegally) NSS (if my DD should be accurate)! 2nd & 3rd legz might get epic. Should move better than $CDIO with better S/S & much higher short-#s. ($CDIO has got 20M+ O/S & most shorted level was 'only' 100M) Gobbling up blue-light specialz and will continue to do so. This ticker is going to fly again VERY shortly. Zero borrow now! Epic squeeze around the corner as it looks to me. Loading-zone before 2nd up-leg get started. Jmho. *NFA
Chart (180day/daily w/ acc./dist.-ind.):
Here $CDIO 180day chart for comparison:
Chart (1y/daily) $CYTO:
$CYTO >>> 6k Filing out: (Back to...) Compliance with Continued Listing Rule
On November 21, 2023, Altamira Therapeutics Ltd., an exempted company limited by shares incorporated in Bermuda (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (the “Staff”) indicating that, based on the Company’s Form 6-K, dated November 21, 2023, the Staff has determined that the Company complies with Nasdaq Listing Rule 5550(b)(1).
$CYTO >>> Global Healthcare Company Celebrates Milestone For This Patent Approval